Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into the clinic, including candidates against Lyme disease and the chikungunya virus.

Valneva at a glance

Commercial vaccines

€m

Total revenues in 2021

Unique vaccine development programs

Integrated

differentiated clinical and pre-clinical assets

robust commercial portfolio

Focused

on prevention of infectious diseases with significant unmet medical need

~700

employees in six countries